when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Wegovy · news · pharmadog

← back to Wegovy

News mentioning Wegovy

85 stories

1dSTAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and morestat

1dEnveda’s exercise-simulating obesity tablet clears early clinical testbiospace

2dNovo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

2dAmylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiabiospace

3dAmylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 winfiercebiotech

6dSkye and Redx form new entity with $125M to advance fibrosis assetsfiercebiotech

7dSTAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and morestat

8dReplimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlightbiospace

9dScholar Rock rejigs approval filing after FDA flags violations at Novo plantbiospace

9dAfter tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’fiercebiotech

9dOpinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugsstat

13dNovo Nordisk’s CFO on the oral Wegovy rollout and beyondfiercebiotech

15dActimed gets back rights to wasting disease drug, ending $126M deal with Faradayfiercebiotech

15dLilly confident in slow and steady Foundayo launch, as ex-US sales shinebiospace

15dLilly, FDA retatrutide biologic dispute comes to a head as submission nearsbiospace

15dLilly climbs, Novo falls as obesity drug battle intensifiesbiopharma dive

15dLilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1biospace

15dNovo CEO sees innovation as a matter of survival amid pipeline setbacksbiospace

15d‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthfiercebiotech

16dNovo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed datafiercebiotech

16dNovo dips 6% on Wegovy pill stumble despite Q2 earnings beatbiospace

20dNovo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%biospace

20d‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spreefiercebiotech

22dFDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s databiopharma dive

22dNovo ordered to face CagriSema fraud claims from shareholders: New Jersey courtbiospace

22dNovo Nordisk fails to dismiss lawsuit over CagriSema readoutfiercebiotech

23dAltimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder winfiercebiotech

27dNovo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomabiopharma dive

28dChutes & Ladders—Biogen R&D vet gets in Formationfiercebiotech

28dLilly, with new data, to seek FDA approval of obesity drug retatrutidebiopharma dive

← prevpage 1 of 3next →